Brief: Oncolytics Biotech Doses First Patient In Phase 1/2 Study Of Gastrointestinal Cancers Therapies
03/11/2021 13:41
Nov 3 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® DOSES FIRST PATIENT IN PHASE 1/2
GOBLET
STUDY EVALUATING PELAREOREP-ANTI-PD-L1 COMBINATION THERAPIES IN
GASTROINTESTINAL CANCERS
Source text for Eikon: ID:nCNWgnMc6a
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer